TIMP‑1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells
datasetposted on 06.09.2013 by Omid Hekmat, Stephanie Munk, Louise Fogh, Rachita Yadav, Chiara Francavilla, Heiko Horn, Sidse Ørnbjerg Würtz, Anne-Sofie Schrohl, Britt Damsgaard, Maria Unni Rømer, Kirstine C. Belling, Niels Frank Jensen, Irina Gromova, Dorte B. Bekker-Jensen, José M. Moreira, Lars J. Jensen, Ramneek Gupta, Ulrik Lademann, Nils Brünner, Jesper V. Olsen, Jan Stenvang
Datasets usually provide raw data for analysis. This raw data often comes in spreadsheet form, but can be any collection of data, on which analysis can be performed.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a protein with a potential biological role in drug resistance. To elucidate the unknown molecular mechanisms underlying the association between high TIMP-1 levels and increased chemotherapy resistance, we employed SILAC-based quantitative mass spectrometry to analyze global proteome and phosphoproteome differences of MCF-7 breast cancer cells expressing high or low levels of TIMP-1. In TIMP-1 high expressing cells, 312 proteins and 452 phosphorylation sites were up-regulated. Among these were the cancer drug targets topoisomerase 1, 2A, and 2B, which may explain the resistance phenotype to topoisomerase inhibitors that was observed in cells with high TIMP-1 levels. Pathway analysis showed an enrichment of proteins from functional categories such as apoptosis, cell cycle, DNA repair, transcription factors, drug targets and proteins associated with drug resistance or sensitivity, and drug transportation. The NetworKIN algorithm predicted the protein kinases CK2a, CDK1, PLK1, and ATM as likely candidates involved in the hyperphosphorylation of the topoisomerases. Up-regulation of protein and/or phosphorylation levels of topoisomerases in TIMP-1 high expressing cells may be part of the mechanisms by which TIMP-1 confers resistance to treatment with the widely used topoisomerase inhibitors in breast and colorectal cancer.